# Groovy Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/groovy-medicine

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Latest round: Angel (Jul 20, 2023)
- Investors on record: 2

## About

Founded in 2022 and based in Hangzhou, China, Groovy Medicine is a pharmaceutical company that focuses on the R&D, production, and sales of new drugs for cancer, neurodegenerative diseases. Professor Xu Li, the company's founder, is a doctoral supervisor at Westlake University, and engages in the R&D field of functional proteomics and complex diseases, and published over 50 papers. In November 2025, Groovy Medicine raised a strategic investment led by new investor Xinghua Dingli Capital, with participation from new investors Hangzhou High-Tech Investment and HangZhou Capital.
Groovy Medicine engages in the R&D of new drugs for complex diseases. It has a disease target discovery and AI drug design platform, which enable to find effective, specific and drug-ready targets, and can greatly accelerate the process of new drug discovery and development. Its drug pipelines have been advanced to the pre-clinical stage. The company generates revenue through the R&D and manufaturing of new drugs for complex diseases.
The company focuses on advancing the clinical trial process of its core pipeline, GW-01, while also accelerating the identification of innovative targets and external collaborations for its high-dimensional drug discovery platform in areas such as neurodegenerative diseases and oncology.

## Funding rounds

- Angel, Jul 20, 2023 — Beijia Investment Management, Westlake University Capital

## Investors

- Beijia Investment Management (https://capitalatlas.ai/funds/beijia-investment-management) — Angel
- Westlake University Capital — Angel